| Aug 13 |
3 Biotech Stocks Poised for a Comeback After Last Week’s Market Meltdown
|
| Aug 12 |
FDA approves Sandoz’s Enzeevu as Eylea biosimilar saga continues
|
| Aug 10 |
Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?
|
| Aug 9 |
HRMY vs. REGN: Which Stock Is the Better Value Option?
|
| Aug 9 |
What Makes Street Analysts Bullish on Regeneron Pharmaceuticals, Inc. (REGN) Now?
|
| Aug 8 |
3 Biotech Stocks With Promising Drug Pipelines: August 2024
|
| Aug 7 |
Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
|
| Aug 7 |
3 Healthcare Stocks Positioned for Possible Market Outperformance
|
| Aug 7 |
Regeneron: Expanded Product Base Taking Root, More Is Certainly On The Way
|
| Aug 6 |
Nvidia, Meta, Netflix Profit Outlooks Sunny Despite Harsh Selling
|
